The Hippo

HOME| ADVERTISING | CONTACT US|

Valcyte for Cytomegalovirus in Children Concord NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Caroline K Dueger, MD, FAAP
(603) 224-2618
215 Mountain Rd
Concord, NH
Specialties
Pediatrics
Gender
Male
Education
Graduation Year: 1960

Data Provided by:
David Stanley Ross, MD
(603) 224-1929
248 Pleasant St Ste 1700
Concord, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Univ Of Pittsburgh Sch Of Med, Pittsburgh Pa 15261
Graduation Year: 1969

Data Provided by:
Dr. Stanley S Lynch
(603) 226-4960
Pleasant St Memorial Bldg
Concord, NH
Specialty
Pediatrics

Fabozzi Scott J Urologist
(603) 224-3388
246 Pleasant Street
Concord, NH
 
Dr. Roger H Wicksman
(603) 224-1929
248 Pleasant St
Concord, NH
Specialty
Pediatrics

Lafontaine Mildred H PHYS
(603) 224-6691
248 Pleasant Street
Concord, NH
 
Thomas M Albushies
(603) 224-1929
248 Pleasant St
Concord, NH
Specialty
Pediatrics

Data Provided by:
Dr. Cynthia Anne Kahn
(910) 432-2912
Office Of Health Management
Concord, NH
Specialty
Pediatrics

Dr. Ursula Susan Kneissl
(603) 228-7200
250 Pleasant St
Concord, NH
Specialty
Pediatrics

Dolly R Courtemanche
(603) 224-1929
248 Pleasant St
Concord, NH
Specialty
Pediatrics

Data Provided by:
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu